Media, investors, advocacy organizations and others, please contact us here.

Sparsentan vs Irbesartanin Patients With Focal Segmental Glomerulosclerosis(FSGS) Without Nephrotic Syndrome in the Phase 3 DUPLEX Trial

Page 1 / 1 100%
Loading...